How can we improve patients’ access to new drugs under uncertainties? : South Korea’s experience with risk sharing arrangements

Table 3 Days between approval and reimbursement and the counts of appraisal for reimbursement of RSA drugs in South Korea

(unit: day, count)
		Total	RSA only	RSA with EEE
All drugs	N	39	21	18
	days between approval and reimbursement	849.4	912.1	776.3
	average number of appraisals^b	1.92	2.24	1.56
Market approval by MFDS before 2014	N	12	10	2
	days between approval and reimbursement	1167.4	1131.4	1347.5
	average number of appraisals^b	2.83	2.70	3.50
Market approval by MFDS in 2014-2015	N	14	5	9
	days between approval and reimbursement	923.7	1010.0	875.8
	average number of appraisals^b	1.64	1.80	1.56
Market approval by MFDS after 2015^a	N	13	6	7
	days between approval and reimbursement	475.9	465.0	485.3
	average number of appraisals^b	1.38	1.83	1.00

The activation date of eculizumab and galsulfase was applied with the refund pilot program (October 1, 2012 and December 1, 2009, respectively)
^auntil the first half of 2019
^bnot including deferred appraisal
MFDS Ministry of Food and Drug Safety, RSA risk sharing arrangement, EEE exemption of economic evaluation

ISSN: 1472-6963